These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 23908178)
1. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Montemurro F; Di Cosimo S; Arpino G Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178 [TBL] [Abstract][Full Text] [Related]
2. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Prat A; Baselga J Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391 [TBL] [Abstract][Full Text] [Related]
3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
4. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065 [TBL] [Abstract][Full Text] [Related]
5. Overcoming endocrine resistance in hormone receptor-positive breast cancer. AlFakeeh A; Brezden-Masley C Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644 [TBL] [Abstract][Full Text] [Related]
6. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. Harbeck N Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480 [TBL] [Abstract][Full Text] [Related]
7. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China. Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380 [TBL] [Abstract][Full Text] [Related]
8. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852 [TBL] [Abstract][Full Text] [Related]
9. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
10. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651 [TBL] [Abstract][Full Text] [Related]
11. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? Wu VS; Kanaya N; Lo C; Mortimer J; Chen S J Steroid Biochem Mol Biol; 2015 Sep; 153():45-53. PubMed ID: 25998416 [TBL] [Abstract][Full Text] [Related]
12. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Gao S; Barber B; Schabert V; Ferrufino C Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480 [TBL] [Abstract][Full Text] [Related]
13. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246 [TBL] [Abstract][Full Text] [Related]
14. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C; Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889 [TBL] [Abstract][Full Text] [Related]
15. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Wilson FR; Varu A; Mitra D; Cameron C; Iyer S Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187 [TBL] [Abstract][Full Text] [Related]
17. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. Matutino A; Joy AA; Brezden-Masley C; Chia S; Verma S Curr Oncol; 2018 Jun; 25(Suppl 1):S131-S141. PubMed ID: 29910656 [TBL] [Abstract][Full Text] [Related]
18. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412 [TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075 [TBL] [Abstract][Full Text] [Related]
20. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]